Genmab A/S (LON:0MGB)

Market Cap	13.48B
Revenue (ttm)	2.66B
Net Income (ttm)	1.00B
Shares Out	n/a
EPS (ttm)	15.78
PE Ratio	13.47
Forward PE	15.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,662
Average Volume	21,686
Open	1,861.75
Previous Close	1,845.48
Day's Range	1,838.00 - 1,869.50
52-Week Range	1,168.50 - 2,151.00
Beta	0.82
RSI	40.54
Earnings Date	Nov 6, 2025

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 2,682
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0MGB

Financial Performance

In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.

Financial numbers in USD